Skip to main content
Back to jobs

Associate Director, Regulatory Affairs, Japan

External
Full-timeRemoteToday
Cross-functional CollaborationLeadership
Cover LetterConnect

Prepare for this interview

Elite

AI-generated questions, company research, and talking points tailored to this role


About the role

As a member of the Regulatory Affairs organization, you will play a critical role in advancing innovative oncology therapies from development through registration and commercialization, helping bring transformative medicines to patients worldwide. The Associate Director, Regulatory Affairs Japan will serve as the regulatory lead for assigned development programs and products in Japan. This individual will be responsible for developing and executing regulatory strategies to support clinical development, registration, and lifecycle management activities. The role will represent Japan Regulatory Affairs on global project teams, contribute to PMDA interactions, and provide strategic regulatory guidance to support successful development and commercialization activities in Japan.

Responsibilities

  • Regulatory Strategy Leadership
  • Lead regulatory activities for assigned programs and products in Japan.
  • Develop and execute regulatory strategies supporting clinical development, registration, and lifecycle management.
  • Conduct regulatory assessments and provide recommendations for development programs.
  • Identify regulatory risks and develop mitigation plans.
  • Provide regulatory guidance to cross-functional teams.
  • Health Authority Leadership
  • Lead PMDA consultations and routine regulatory interactions with appropriate management support.
  • Prepare briefing packages, meeting materials, and responses to health authority inquiries.
  • Lead or support J-NDA submissions and post-approval activities.
  • Ensure alignment of Japanese regulatory requirements with global development plans.
  • Global and Cross-Functional Collaboration
  • Represent Japan Regulatory Affairs on global project teams.
  • Collaborate with Clinical Development, Clinical Operations, Medical Affairs, Safety, CMC, Quality, and Medical Writing functions.
  • Contribute to project decision-making and regulatory planning.
  • Vendor and CRO Management
  • Manage regulatory consultants, vendors, and CRO partners supporting Japan activities.
  • Monitor timelines, deliverables, budgets, and quality of outsourced work.
  • People Leadership
  • Mentor junior regulatory colleagues and contribute to team development.
  • May provide supervisory responsibilities for contractors or junior staff.
  • Required Skills, Experience and Education:
  • Bachelor's degree in Life Sciences, Pharmacy, Medicine, or related discipline; advanced degree preferred.
  • Typically 8+ years of pharmaceutical or biotechnology industry experience, including significant Regulatory Affairs experience.
  • Experience supporting regulatory strategy for clinical development and registration programs.
  • Strong knowledge of Japanese pharmaceutical regulations, PMDA processes, and ICH guidelines.
  • Excellent communication and collaboration skills.
  • Preferred Skills:
  • Oncology drug development experience.
  • PMDA consultation experience.
  • Experience supporting NDA/J-NDA submissions.
  • Experience working on global development programs.
  • Experience managing vendors or CROs.
  • Leveling Considerations
  • Associate Director
  • Independently leads regulatory activities for assigned programs.
  • Provides strategic regulatory input and manages external partners.
  • Leads PMDA interactions with appropriate support.

Benefits

Health insurance

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.


Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience

Interested in this role?

Apply on the company's website.

Cover LetterConnect